The Wall Street Journal: Endo Pharma to withdraw application for new opioid painkiller formulation

Endo Pharmaceuticals PLC has decided to withdraw its supplemental new drug application for the extended-release version of its Opana opiod painkiller but said it would continue to work with the U.S. Food and Drug Administration to advance the drug.

Shares in the company ENDP, +3.23% added 2.4% to $23.55 in premarket trading.

The pharmaceutical company, which is domiciled in Dublin and has U.S. headquarters in Malvern, Pa., plans to continue collecting and analyzing data on the drug and could refile.

“We anticipate the generation of additional data, and we will seek collaboration with FDA to appropriately advance Opana ER,” said Dr.

>>> Original Source <<<